Rachael E Tennant
Overview
Explore the profile of Rachael E Tennant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Snodin D, Trejo-Martin A, Ponting D, Smith G, Czich A, Cross K, et al.
Chem Res Toxicol
. 2024 Feb;
37(2):181-198.
PMID: 38316048
A thorough literature review was undertaken to understand how the pathways of -nitrosamine transformation relate to mutagenic potential and carcinogenic potency in rodents. Empirical and computational evidence indicates that a...
2.
Boby M, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson M, et al.
Science
. 2023 Nov;
382(6671):eabo7201.
PMID: 37943932
We report the results of the COVID Moonshot, a fully open-science, crowdsourced, and structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease. We discovered...
3.
Tennant R, Ponting D, Thresher A
Regul Toxicol Pharmacol
. 2023 Jul;
143:105460.
PMID: 37495012
Mutagenicity data is a core component of the safety assessment data required by regulatory agencies for acceptance of new drug compounds, with the OECD-471 bacterial reverse mutation (Ames) assay most...
4.
Thomas R, Tennant R, Oliveira A, Ponting D
Chem Res Toxicol
. 2022 Oct;
35(11):1997-2013.
PMID: 36302501
The discovery of carcinogenic nitrosamine impurities above the safe limits in pharmaceuticals has led to an urgent need to develop methods for extending structure-activity relationship (SAR) analyses from relatively limited...
5.
Trejo-Martin A, Bercu J, Thresher A, Tennant R, Thomas R, Cross K, et al.
Regul Toxicol Pharmacol
. 2022 Aug;
135:105247.
PMID: 35998738
Under ICH M7, impurities are assessed using the bacterial reverse mutation assay (i.e., Ames test) when predicted positive using in silico methodologies followed by expert review. N-Nitrosamines (NAs) have been...
6.
Chilton M, Api A, Foster R, Gerberick G, Lavelle M, Macmillan D, et al.
Regul Toxicol Pharmacol
. 2022 Jun;
133:105200.
PMID: 35662638
The Dermal Sensitisation Thresholds (DST) are Thresholds of Toxicological Concern, which can be used to justify exposure-based waiving when conducting a skin sensitisation risk assessment. This study aimed to update...
7.
Ponting D, Burns M, Foster R, Hemingway R, Kocks G, Macmillan D, et al.
Methods Mol Biol
. 2022 Feb;
2425:435-478.
PMID: 35188642
Lhasa Limited have had a role in the in silico prediction of drug and other chemical toxicity for over 30 years. This role has always been multifaceted, both as a...
8.
Foster R, Fowkes A, Cayley A, Thresher A, Werner A, Barber C, et al.
Genes Environ
. 2020 Sep;
42:27.
PMID: 32983286
The use of in silico predictions for the assessment of bacterial mutagenicity under the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M7 guideline is...
9.
Thresher A, Foster R, Ponting D, Stalford S, Tennant R, Thomas R
Regul Toxicol Pharmacol
. 2020 Aug;
116:104749.
PMID: 32777431
The control of potentially mutagenic impurities in pharmaceutical products is of key importance in assessing carcinogenic risk to humans. The recent discovery of nitrosamine impurities in several marketed pharmaceuticals has...
10.
Tennant R, Guesne S, Canipa S, Cayley A, Drewe W, Honma M, et al.
Mutagenesis
. 2018 Oct;
34(1):111-121.
PMID: 30281100
As part of the hazard and risk assessment of chemicals in man, it is important to assess the ability of a chemical to induce mutations in vivo. Because of the...